Will Moderna Soar on Nov. 6?

Biotech stock Moderna (NASDAQ:MRNA) has soared in the triple digits this year, powering past even some of the market's biggest artificial intelligence (AI) players such as Nvidia and Micron Technology. AI has been the space fueling S&P 500 momentum over the past three years, so it may seem surprising to see a healthcare player surpassing the tech giants.

But Moderna has attracted investor attention for good reason. The company is an expert in the high-potential messenger RNA technology -- a technology that Moderna proved could work when it won approval for its coronavirus vaccine in the early days of the pandemic. And Moderna is advancing successfully along the path to treating one of today's biggest healthcare challenges: cancer. The company's personalized cancer vaccine is involved in 10 clinical trials, including a phase 3 study in melanoma that recently delivered strong results.

Now, with a fresh catalyst coming up on Nov. 6, you may be wondering if this exciting biotech stock will take off once again. Let's find out.

Continue reading